Panbesy Dosage & Drug Information

Indications/Uses

Adjunct to treatment of patients w/ moderate to severe obesity.

Dosage/Direction for Use

Adult & childn >12 yr One 15-mg cap daily at breakfast & again at lunchtime if required. Alternatively, one 30-mg cap at breakfast. Taking any later than lunchtime may cause trouble sleeping at night.

Administration

Should be taken with food.

Contraindications

Hypersensitivity to phentermine HCl or sympathomimetic amines. Epilepsy. Hyperexcitability. Advanced arteriosclerosis. Severe HTN. Patients w/ CV disease. Hyperthyroidism. Glaucoma. Patients w/ history of drug abuse. During or 14 days following administration of MAOIs. Childn <12 yr.

Special Precautions

Possibility of abuse. Discontinue when tolerance occurs. Do not exceed recommended dose in an attempt to increase anorectic effect. Caution in patients w/ mild HTN. Insulin requirements in DM may be altered. May cause blurred vision, dizziness or tiredness in some patients. Do not use during pregnancy & lactation. Avoid in childn <12 yr.

Adverse Reactions

Dry mouth, restlessness, headache, insomnia, irritability, dizziness, tremor.

View ADR Reporting Link

Drug Interactions

Do not co-administer w/ MAOIs or w/in 14 days of stopping MAOI treatment. Risk of severe HTN w/ β-blockers. Increased risk of CV effects w/ TCAs. Increased risk of cardiac arrhythmias w/ volatile anaesth. Decreased hypotensive effect of guanethidine.

MIMS Class

Anti-Obesity Agents

ATC Classification

A08AA01 - phentermine ; Belongs to the class of centrally acting antiobesity products. Used in the treatment of obesity.

Regulatory Classification

DD, P₁S₁S₃

Presentation/Packing

Form

Panbesy cap 15 mg

Packing/Price

200's

Form

Panbesy cap 30 mg

Packing/Price

200's

Panbesy

phentermine

Manufacturer:

Eurodrug

Distributor:

DCH Auriga - Healthcare